only with
Gland Pharma Ltd.
Gland Pharma
Gland Pharma Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Mid-cap - With a market cap of ₹400.40 Cr.
| EX-Date | Purpose |
|---|---|
| 21 07 2021 | Quarterly Results |
| 22 10 2021 | Quarterly Results |
| 21 01 2022 | Quarterly Results |
| 19 05 2022 | Audited Results |
| 20 07 2022 | Quarterly Results |
| 26 10 2022 | Quarterly Results |
| 23 01 2023 | Quarterly Results |
| 18 05 2023 | A.G.M. |
| 18 05 2023 | Audited Results |
| 07 08 2023 | |
| 07 08 2023 | Quarterly Results |
| 06 11 2023 | Quarterly Results |
| 14 02 2024 | Quarterly Results |
| 04 11 2024 | Quarterly Results |
| 03 02 2025 | Quarterly Results |
| 20 05 2025 | Audited Results & Final Dividend |
| 05 08 2025 | Quarterly Results |
| 03 11 2025 | Quarterly Results |
| 28 01 2026 | Quarterly Results |
| 15 05 2026 | Final Dividend & Audited Results |
| 10 08 2026 | Quarterly Results |
News
Gland Pharma’s consolidated net profit jumps 97% in Q4
The total consolidated income of the company increased by 26.23% at Rs 1,854.26 crore for Q4FY26
Gland Pharma gets USFDA’s tentative nod for Brimonidine Tartrate Ophthalmic Solution
The product is indicated to relieve redness of the eye
Gland Pharma gets USFDA’s approval for Zoledronic Acid Injection
This Product is indicated to treat Hypercalcemia of Malignancy and Multiple Myeloma and Bone Metastases of Solid Tumors
Gland Pharma gets nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
This product is indicated for the treatment of ocular itching associated with allergic conjunctivitis
Gland Pharma reports 12% rise in Q2 consolidated net profit
The consolidated total income of the company increased by 7.20% at Rs 1,571.04 crore for Q2FY26
Gland Pharma receives USFDA’s approval for Vasopressin in 5% Dextrose RTU Injection
According to IQVIA, the product had US sales of approximately $45 million for the twelve months ending June 2025
Gland Pharma gets USFDA’s nod for Cangrelor for Injection
The product had US sales of around $122 million for the twelve months ending June 2025
Gland Pharma gets USFDA’s approval for Norepinephrine Bitartrate
The company is the exclusive First-to-File and is eligible for 180 days of generic drug exclusivity
Gland Pharma reports 50% jump in Q1 consolidated net profit
The total consolidated income of the company increased by 7.57% at Rs 1563.15 crore for Q1FY26
Gland Pharma gets GMP Compliance Certificate for Pashamylaram facility
The company has received certificate of GMP for aseptically prepared Powder for injection, infusion and inhalation
Gland Pharma gets EIR from USFDA for Visakhapatnam facility
The said inspection was conducted between February 19, 2025 and February 25, 2025
Gland Pharma’s subsidiary gets 11 observations for Fontenay manufacturing facility
There will be no disruption in the manufacturing operations due to this final inspection report
Gland Pharma gets USFDA’s approval for Angiotensin II Acetate Injection
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), GIAPREZA of La Jolla Pharma LLC
Gland Pharma gets USFDA’s nod for Latanoprostene Bunod Ophthalmic Solution
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Gland Pharma receives USFDA’s approval for Acetaminophen Injection
This product is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
USFDA concludes pre-approval inspection at Visakhapatnam facility of Gland Pharma
The said inspection was concluded with three form 483 observations
Gland Pharma reports 7% rise in Q3 consolidated net profit
Total consolidated income of the company decreased by 8.85% at Rs 1442.55 crore for Q3FY25
Gland Pharma gets EIR from USFDA for Pashamylaram facility
USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024
Gland Pharma gets EIR from USFDA for Hyderabad facility
USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 22, 2024 and July 25, 2024
Gland Pharma gets USFDA’s approval for Phytonadione Injectable Emulsion
The Product is bioequivalent and therapeutically equivalent to the RLD, Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
Gland Pharma gets USFDA’s nod for Latanoprost Ophthalmic Solution
This Product is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Gland Pharma reports 16% fall in Q2 consolidated net profit
Consolidated total income of the company increased by 2.73% at Rs 1,465.49 crore for Q2FY25
Gland Pharma gets USFDA’s approval for Eribulin Mesylate Injection
The company expects to launch this product in the near term through its marketing partner
Gland Pharma gets EIR for Pashamylaram Facility
The Pre-Market Inspection was conducted between August 23, 2023 and August 26, 2023
Gland Pharma gets USFDA’s tentative nod for Angiotensin II Injection
The company will launch the product with its marketing partner on receipt of final approval
Gland Pharma gets EIR for VSEZ Sterile Oncology Facility
The GMP Inspection was conducted by USFDA between July 20, 2023 and July 28, 2023
USFDA concludes inspection at Gland Pharma’s Pashamylaram Facility
The company has received Establishment Inspection Report
USFDA conducts inspection at Gland Pharma’s Pashamylaram Facility in Hyderabad
The company has received 2 observations on Form 483 with respect to ANDA filed for the product to be manufactured in a PEN device
Gland Pharma gets EIR for Dundigal facility
USFDA had conducted inspection at the said manufacturing facility from July 03, 2023 to July 14, 2023
USFDA concludes GMP inspection at Gland Pharma’s Visakhapatnam facility
The inspection was concluded with (Zero) 483 observations and a classification of No Action Indicated
USFDA concludes GMP inspection at Gland Pharma’s Dundigal facility
The inspection was concluded with (1) 483 Observation
USFDA concludes PAI, GMP inspection at Gland Pharma’s Pashamylaram facility
The inspection was concluded with (1) 483 observation
Gland Pharma reports 72% fall in Q4 consolidated net profit
Total consolidated income of the company decreased by 29.47% at Rs 823.95 crore for Q4FY23
Gland Pharma planning to invest Rs 400 crore to expand Telangana’s existing facility
The expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places
USFDA conducts inspection at Gland Pharma’s API Facility in Visakhapatnam
The inspection has been completed with Zero observations
Gland Pharma reports 15% fall in Q3 consolidated net profit
Total consolidated income of the company decreased by 9.85% to Rs 999.80 crore for Q3FY23
Gland Pharma receives EIR from US FDA for Dundigal Facility at Hyderabad
Earlier, the Pre-Market Inspection covering US FDA’s Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) was conducted between August 22-25, 2022
Gland Pharma enters into put option agreement to acquire 100% stake in Cenexi Group
The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones
Gland Pharma reports 20% fall in Q2 consolidated net profit
Total consolidated income of the company decreased by 1.91% at Rs 1110.03 crore for Q2FY23